
Biomednewsbreaks - Clene Inc. (NASDAQ: CLNN) Reports Q1 Results, Advances CNM-Au8 Toward Potential Accelerated Approval ...
(MENAFN- Investor Brand Network) Clene (NASDAQ: CLNN) announced first quarter 2025 financial results and progress on its CNM-Au8 program for ALS and MS. The company is preparing for a potential NDA submission under the FDA's Accelerated Approval …